Scat Y, Morin Y, Morel C, Haut J
Service de Biologie Médicale, Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts, Paris.
J Fr Ophtalmol. 1995;18(12):758-62.
A new abnormality in the coagulation system, the resistance to activated protein C, has appeared among the numerous hereditary modifications which predispose patients to deep-vein thrombosis. The molecular abnormality responsible for the resistance to activated protein C is due to a mutation of an amino acid in the 506 position (Arg-->Gln) at the level of the factor V, designated under the name of factor V Leiden.
The authors wished to search for this alteration of the haemostasis in 106 patients with retinal venous occlusion hospitalized in Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts (Paris).
In our study of 106 patients presenting a retinal venous occlusion, the resistance to activated protein C was the most frequent coagulation abnormality found (4.71%), when compared with the other deficits of the inhibitors of the clotting system: protein S (2.80%), antithrombin III (0.94%) et protein C (0%).
The test of resistance to activated protein C should be recommanded in cases of retinal venous occlusion, particularly in the search for a cause of thrombosis in young patients or in recurrent thrombosis.
在众多使患者易患深静脉血栓形成的遗传性改变中,出现了一种凝血系统的新异常,即对活化蛋白C的抵抗。导致对活化蛋白C抵抗的分子异常是由于因子V水平上第506位氨基酸的突变(精氨酸→谷氨酰胺),命名为因子V莱顿。
作者希望在巴黎国家眼科中心(Quinze-Vingts)住院的106例视网膜静脉阻塞患者中寻找这种止血改变。
在我们对106例视网膜静脉阻塞患者的研究中,与凝血系统抑制剂的其他缺陷(蛋白S:2.80%;抗凝血酶III:0.94%;蛋白C:0%)相比,对活化蛋白C的抵抗是最常见的凝血异常(4.71%)。
对于视网膜静脉阻塞患者,尤其是在寻找年轻患者血栓形成原因或复发性血栓形成原因时,应推荐进行活化蛋白C抵抗检测。